Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance mechanisms...
[1]First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer [3]Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. [4...
17. Camidge DR, Kim DW, Tiseo M, et al. Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-smallcell lung cancer and brain metastases in two clinical trials. J Clin Oncol. 2018;36(...
2. Pignon JP, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008 Jul 20;26(21):3552-3559. 3. Chia PL, et al. Prevalence and natural history of A...
Camidge DR, Hirsch FR, Varella-Garcia M, et al. Finding ALK-positive lung cancer: what are we really looking for? J Thorac Oncol 2011;6: 411- 413.Finding ALK-Positive Lung Cancer: What Are We Really Looking for?[J] . D. Ross Camidge,Fred R. Hirsch,Marileila Varella-Garcia,Wilbur...
[9]First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study [10] Solomon BJ, et al. First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CRO...
ALK-positive lung cancer: a moving target Article16 February 2023 Introduction Anaplastic lymphoma kinase (ALK) gene alterations are gaining more attention as pan-cancer markers in both solid and hematological malignancies. ActivatingALKalterations (mutations, amplifications, fusions/rearrangements) are foun...
Figure 1. Proposed therapeutic algorithm in ALK-positive NSCLC. ALK, anaplastic lymphoma kinase; cfDNA, cell-free DNA; NSCLC, non-small cell lung cancer; I.O. immunotherapy.References 1. P.L. Chia, T. John, A. Dobrovic, et al. Prevalence and natural history of ALK positive non-small-...
“Xalkori transformed the treatment of ALK-positive non-small cell lung cancer as the first biomarker-driven therapy for that disease, and this approval is a notable milestone in our journey to continue to follow the science to address cancers with significant unmet need...
3. Wu YL,et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 Apr 11;390(14):1265-1276. 4. Pignon JP, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the ...